Effect of daily caffeine consumption on dose of dexmedetomidine for inducing sedation during spinal anesthesia
Not Applicable
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0005686
- Lead Sponsor
- Chonnam National University Hospital Hwasun Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Scheduled surgery under spinal anesthesia
ASA PS 1-3
19-70 years
Exclusion Criteria
Contraindication in regional anesthesia
Taking CNS drugs
Currently in severe pain
With liver or kidney disease
With cardiovascular, respiratory, nervous system disease
Conversion to general anesthesia
High level block of T4 or higher
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount of dexmedetomidine required to achieve BIS 70 based on daily caffeine intake
- Secondary Outcome Measures
Name Time Method Additional midazolam required to become BIS 70
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does caffeine consumption modulate adrenergic receptor activity affecting dexmedetomidine sedation in spinal anesthesia?
What comparative efficacy data exist for caffeine-adjusted dexmedetomidine vs. standard sedation protocols in musculoskeletal surgery?
Which genetic biomarkers (e.g., CYP1A2 polymorphisms) predict altered dexmedetomidine requirements in caffeine-consuming patients?
What are the safety profiles of combining adenosine receptor antagonists with alpha-2 agonists during regional anesthesia?
How do methylxanthine compounds like caffeine influence sedative drug dosing in spinal anesthesia for connective tissue disorders?